Cargando…

Bladder Cancer Immunotherapy: BCG and Beyond

Mycobacterium bovis bacillus Calmette-Guérin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response. While BCG treatment is the curr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Askeland, Eric J., Newton, Mark R., O'Donnell, Michael A., Luo, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388311/ https://www.ncbi.nlm.nih.gov/pubmed/22778725 http://dx.doi.org/10.1155/2012/181987

Ejemplares similares

Recognition and Treatment of BCG Failure in Bladder Cancer
por: Lightfoot, Andrew J., et al.
Publicado: (2011)

BCG in Bladder Cancer Immunotherapy
por: Jiang, Song, et al.
Publicado: (2022)

Treatment options in non-muscle-invasive bladder cancer after BCG failure
por: Brooks, Nathan A., et al.
Publicado: (2015)

Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer
por: Luo, Yi, et al.
Publicado: (2011)

Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2016)

Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer
por: Kamat, Ashish M., et al.
Publicado: (2017)

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer
por: Bevers, R F M, et al.
Publicado: (2004)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
por: Kamat, Ashish M., et al.
Publicado: (2017)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
por: Vilares, Ana T., et al.
Publicado: (2022)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
por: Kamat, Ashish M., et al.
Publicado: (2017)

Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins
por: Saban, Marcia R, et al.
Publicado: (2007)

Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-α
por: Saban, Marcia R, et al.
Publicado: (2008)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020)

Renal Tuberculosis Following Intravesical Bacillus Calmette–Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer
por: Bajramovic, Senad, et al.
Publicado: (2020)

Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis
por: Chen, Xingfeng, et al.
Publicado: (2023)

BCG immunotherapy of rat sarcomata.
por: Baldwin, R. W., et al.
Publicado: (1973)

BCG-Mediated Bladder Cancer Immunotherapy: Identifying Determinants of Treatment Response Using a Calibrated Mathematical Model
por: Rentsch, Cyrill A., et al.
Publicado: (2013)

Vascular graft infections caused by Mycobacterium bovis BCG after BCG immunotherapy for non-muscle-invasive bladder cancer: Case report and review of literature
por: Arsuffi, Stefania, et al.
Publicado: (2023)

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
por: Moreo, Eduardo, et al.
Publicado: (2022)

Polymorphisms of genes encoding cytokines predict the risk of high-grade bladder cancer and outcomes of BCG immunotherapy
por: KRAJEWSKI, WOJCIECH, et al.
Publicado: (2020)

Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer
por: Adamkiewicz, Mateusz, et al.
Publicado: (2021)

Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer’s Disease and Parkinson’s Disease
por: Klinger, Danielle, et al.
Publicado: (2021)

Intravesical Treatments of Bladder Cancer: Review
por: Shen, Zancong, et al.
Publicado: (2008)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

BCG Immunotherapy of a Rat Sarcoma
por: Baldwin, R. W., et al.
Publicado: (1973)

Nanotechnology and cancer: improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles
por: Sweeney, Sean K, et al.
Publicado: (2016)

Immunotherapy for bladder cancer
por: Fuge, Oliver, et al.
Publicado: (2015)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors
por: Sun, Kai, et al.
Publicado: (2021)

Immunotherapy With Bacillus Calmette-Guerin (BCG) in a 16-Year-Old With Urothelial Bladder Carcinoma
por: Martinez-Thomas, Jose M, et al.
Publicado: (2022)

Evaluating the neonatal BCG vaccination programme in Ireland
por: Usher, Cara, et al.
Publicado: (2016)

Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy
por: Lima, L, et al.
Publicado: (2013)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Reparameterized multiobjective control of BCG immunotherapy
por: Yue, Rongting, et al.
Publicado: (2023)

Extracellular Vesicles in Bladder Cancer: Biomarkers and Beyond
por: Liu, Yu-Ru, et al.
Publicado: (2018)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer
por: Lim, Chun Jye, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7t52g22a4pn8drq13cj5fc7pf6